Welcome to our dedicated page for Creative Med Technology Hldgs news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Med Technology Hldgs stock.
Creative Medical Technology Holdings Inc. (CELZ) is a biotechnology innovator advancing stem cell therapies for sexual health, chronic pain, and endocrine disorders. This page provides investors and industry observers with timely updates on clinical developments, regulatory milestones, and strategic partnerships driving the company’s regenerative medicine pipeline.
Access verified press releases and news articles covering CELZ’s research progress, including updates on its hypoimmune iPSC platform, AlloStem therapies, and licensing agreements. Content spans clinical trial results, intellectual property announcements, and collaborations in AI-driven drug discovery.
Key updates include advancements in non-invasive treatments for erectile dysfunction, infertility solutions, and chronic pain management protocols. Users will find essential information on FDA communications, trial design approvals, and peer-reviewed study publications.
Bookmark this page for centralized access to CELZ’s latest innovations in cellular therapy. Check regularly for objective reporting on developments impacting the company’s position in regenerative medicine markets.
Creative Medical Technology Holdings (NASDAQ: CELZ) has received FDA clearance for expanded dose escalation in its Phase 1/2 trial of StemSpine® using AlloStem™ (CELZ-201-DDT), a cell therapy for chronic lower back pain caused by degenerative disc disease.
The trial's interim blinded data shows statistically significant pain reduction and improved mobility among participants. Key highlights include:
- No dose-limiting toxicities or serious adverse events reported at trial's halfway point
- Study employs minimally invasive ultrasound-guided injection with 4:1 treatment-to-placebo ratio
- Both Data Safety Monitoring Board (DSMB) and Institutional Review Board (IRB) have approved the new dosing strategy
The company reports enrollment remains on track, with final data expected to inform future clinical and regulatory strategies, potentially accelerating the pathway toward a pivotal Phase 3 trial for Biologics License Application (BLA) submission.
Creative Medical Technology Holdings (NASDAQ: CELZ) has secured agreements for the immediate exercise of warrants, generating approximately $3.7 million in gross proceeds. The agreement involves existing warrant holders purchasing 837,104 shares at $4.42 per share, with these shares already registered under Form S-1.
In exchange for the immediate cash exercise, CELZ will issue new unregistered warrants for up to 1,674,208 shares at an exercise price of $3.75 per share, exercisable for five years following shareholder approval. The transaction, with Roth Capital Partners as financial advisor, is expected to close around March 6, 2025.
The company plans to use the net proceeds for working capital and general corporate purposes. The new warrants are offered through private placement and will require SEC registration for resale of the underlying shares.
Creative Medical Technology Holdings (NASDAQ: CELZ) supports President Donald J. Trump’s executive order to expand access to in vitro fertilization (IVF). This aligns with their OvaStem® program, which has shown an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient’s own eggs, with no safety concerns up to five years post-treatment. OvaStem® offers a novel alternative to traditional IVF by using a patient’s own cells, particularly benefiting those with Primary Ovarian Insufficiency (POI), who typically face a 5-10% chance of spontaneous pregnancy.
OvaStem® integrates the company's AlloStem® platform, already in two FDA-cleared U.S. clinical trials. Creative Medical Technology Holdings has also filed for Orphan Drug Designation for POI. The executive order, signed on February 18, 2025, mandates recommendations within 90 days to lower IVF costs, currently ranging from $12,000 to $25,000 per cycle. This initiative aims to make advanced fertility technologies more accessible.
CEO Timothy Warbington and Clinical Operations Director Courtney Bartlett emphasized the company’s commitment to providing safe, effective, and affordable infertility solutions. The company continues to advance its portfolio of regenerative medicine technologies to empower families and drive shareholder value.
Creative Medical Technology Holdings (NASDAQ: CELZ) has released mid-term follow-up data from its StemSpine® pilot study using AlloStem™ cells for chronic lower back pain treatment. The study showed remarkable results with over 90% of patients reporting no opioid use three years after the procedure, alongside an 80% reduction in pain scores and over 60% improvement in Oswestry Disability Index scores.
StemSpine® is a non-surgical, ultrasound-guided procedure utilizing AlloStem™, an 'off-the-shelf' donor-derived cell therapy. The procedure demonstrated strong safety with only one patient requiring reintervention at the three-year mark and no serious adverse events reported. The company is currently conducting an FDA-cleared Phase 1/2 ADAPT clinical trial, which is seeing strong enrollment driven by these positive pilot study results.
Creative Medical Technology Holdings (NASDAQ: CELZ) has announced promising one-year follow-up data from its AlloStem™ (CELZ-201) Type 2 Diabetes pilot study. The trial demonstrated an 80% overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels, with no serious adverse effects reported.
The study involved 20 patients, split equally between CELZ-201 treatment and optimized medical therapy. The treatment utilized the same infusion procedure approved for the company's FDA-cleared Type 1 Diabetes clinical trial. CELZ-201 is an off-the-shelf, universal allogenic cell line developed by the company.
Based on these results, Creative Medical Technology plans to advance AlloStem's development for late-stage Type 2 Diabetes treatment and explore additional therapeutic applications to expand their pipeline, which includes CELZ-201 for early-stage Type 1 Diabetes and CELZ-101 for brittle Type 1 Diabetes.
Creative Medical Technology Holdings (NASDAQ: CELZ) has expanded its collaboration with Greenstone Biosciences to enhance its iPSC platform development for diabetes treatment. The partnership will leverage Artificial Intelligence to advance their proprietary hypoimmune iPSC technology, including iPSC-derived pancreatic islet cells currently in clinical trials.
The collaboration aims to identify small molecules that enhance insulin secretion and implement multi-gene editing to develop next-generation hypoimmune iPSC lines with improved stealth, survival, and differentiation capabilities. The company expects this AI-driven approach to reduce R&D time by approximately 50% and generate millions in cost savings.
A key focus is addressing the challenge of immunosuppression in stem cell-based therapies, which can cause severe side effects. The development of multi-gene edited hypoimmune iPSCs aims to eliminate the need for immunosuppression, potentially improving patient outcomes in cell-based regenerative therapies.
Creative Medical Technology Holdings (NASDAQ: CELZ) has reported positive initial data from the first cohort of its Phase 1/2 clinical trial of CELZ-201-DDT, a stem cell-based treatment for chronic back pain caused by degenerative disc disease (DDD). The first cohort, consisting of 8 treated patients and 2 placebo recipients, completed the study phase successfully with no dose-limiting toxicities or serious adverse events.
The blinded preliminary data indicates promising therapeutic potential in pain relief and functionality improvement. The independent Data Safety Monitoring Board (DSMB) has recommended proceeding to the next cohort as planned. Enrollment for the second cohort is expected in Q1 2025.
Creative Medical Technology Holdings announced a successful independent interim safety review by the Data Safety Monitoring Board (DSMB) for its ADAPT clinical trial of CELZ-201, a perinatal tissue derived cell product for chronic lower back pain treatment. The DSMB reviewed safety data from the first five dosed patients and approved trial continuation, following a 30-day dose-limiting toxicity assessment. The ADAPT trial is a double-blind, randomized, placebo-controlled, dose-escalation study evaluating CELZ-201's safety and efficacy when administered intramuscularly. The treatment targets approximately 16 million US patients suffering from chronic lower back pain associated with degenerative disc disease.
Creative Medical Technology Holdings (NASDAQ: CELZ) has announced a $1.85 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 418,552 shares at $4.42 per share. Additionally, in a concurrent private placement, the company will issue warrants to purchase up to 837,104 shares with an exercise price of $4.42 per share, exercisable upon stockholder approval and valid for five years. Roth Capital Partners is the exclusive placement agent. The proceeds will be used for working capital and general corporate purposes. The closing is expected around October 23, 2024.
Creative Medical Technology Holdings (NASDAQ: CELZ) has initiated a program to diagnose and treat patients exposed to biological and chemical weapons. The program combines Artificial Intelligence (AI) with the company's proprietary human induced pluripotent stem cells (iPSC) from its iPSCelz® program. AI will be used to identify damage in exposed patients, and based on the clinical diagnosis, the company's validated iPSC Inducible Pluripotent Mesenchymal Cells will be used for personalized treatment. This initiative aligns with Creative Medical Technology's focus on regenerative approaches to immunotherapy, urology, neurology, and orthopedics.
